SGLT-2 Inhibitors and Circulating Progenitor Cells in Diabetes

Gian Paolo Fadini

doi:10.1016/j.cmet.2020.04.002

SGLT-2 Inhibitors and Circulating Progenitor Cells in Diabetes

Cell Metab. 2020 May 5;31(5):883. doi: 10.1016/j.cmet.2020.04.002. Epub 2020 Apr 16.

Author

Gian Paolo Fadini¹

Affiliation

¹ Department of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy. Electronic address: gianpaolo.fadini@unipd.it.

PMID: 32302526
DOI: 10.1016/j.cmet.2020.04.002

Abstract

Hess et al. recently hypothesized that shifts in circulating progenitor cell populations may drive cardiovascular protection by SGLT-2 inhibitors in patients with type 2 diabetes. In this Letter, Fadini challenges that interpretation and discusses previous findings from an independent randomized placebo-controlled trial indicating that cardiovascular protection by SGLT-2 inhibitors may not directly involve circulating stem/progenitor cells.

Publication types

Letter
Comment

MeSH terms

Benzhydryl Compounds
Diabetes Mellitus, Type 2* / drug therapy
Glucosides
Humans
Hypoglycemic Agents
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
Stem Cells

Substances

Benzhydryl Compounds
Glucosides
Hypoglycemic Agents
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors
empagliflozin